Page 49 - Priority Review News Today

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that its lead...

The FDA has granted a priority review to the biologics license application seeking the approval of zolbetuximab for the first-line treatment of patients with unresectable, locally advanced or metastatic, HER2-negative, gastric or gastroesophageal junction adenocarcinoma whose tumors are Claudin18.2 positive.

Zolbetuximab get Priority Review for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

After decades of intense scientific research into developing gene editing technologies, and more than a few setbacks, the field has produced a number of success stories in recent years,...

The study's lead author said patients would experience improved quality of life due to fewer transfusions and fewer trips to the clinic to receive treatment.

FDA approves Roctavian, the first adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A.

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology Meeting Results presented across...

An FDA committee voted unanimously that lecanemab-irmb (Leqembi) shows clinical benefit for the treatment of Alzheimer disease.

/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of...

SHANGHAI, China and CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has